Search Within

Bob Tingkan Li

Formats
  1. Meeting Abstract (143)
  2. Journal Article (122)
  3. Review (7)
  4. Editorial (4)
  5. Conference Paper (1)
  6. Correspondence (1)
  7. Research Letter (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (279)
  3. Thoracic Oncology (279)
  4. GSK Faculty (133)
  5. Department of Pathology and Laboratory Medicine (120)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (111)

More Groups

People
  1. Charles Rudin (72)
  2. Alexander Drilon (65)
  3. Maria Arcila (64)
  4. Mark Kris (57)
  5. Michael Offin (53)
  6. Michael Berger (49)

More People

Years
  1. 2025 (7)
  2. 2024 (39)
  3. 2023 (33)
  4. 2022 (29)
  5. 2021 (38)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (64)
  2. Journal of Thoracic Oncology (37)
  3. Annals of Oncology (28)
  4. Clinical Cancer Research (14)
  5. Cancer Research (13)
  6. JCO Precision Oncology (9)

More Publications

Publishers
  1. American Society of Clinical Oncology (76)
  2. Elsevier Inc. (50)
  3. Oxford University Press (38)
  4. American Association for Cancer Research (36)
  5. Nature Publishing Group (15)
  6. Elsevier Ireland Ltd. (6)

More Publishers

Results (279)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diverse alterations associated with resistance to KRAS(G12C) inhibition
    Journal Article

    Zhao, Y.; Murciano-Goroff, Y. R.; Xue, J. Y.; Ang, A.; Lucas, J.; Mai, T. T.; Da Cruz Paula, A. F.; Saiki, A. Y.; Mohn, D.; Achanta, P.; more...
    Nature (2021)

    Fulltext@MSK | Save
  • Efficacy of sotorasib in KRAS p.G12C-mutated NSCLC with stable brain metastases: A post-hoc analysis of CodeBreaK 100
    Meeting Abstract

    Ramalingam, S.; Skoulidis, F.; Govindan, R.; Velcheti, V.; Li, B.; Besse, B.; Dy, G.; Kim, D.; Schuler, M.; Vincent, M.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Genomic profiles and potential determinants of response and resistance in KRAS p.G12C-mutated NSCLC treated with sotorasib
    Meeting Abstract

    Skoulidis, F.; Schuler, M.; Wolf, J.; Barlesi, F.; Price, T.; Dy, G.; Govindan, R.; Borghaei, H.; Falchook, G.; Li, B.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS(G12C) inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101)
    Meeting Abstract

    Hong, D. S.; Strickler, J. H.; Fakih, M.; Falchook, G. S.; Li, B. T.; Durm, G. A.; Burns, T. F.; Ramalingam, S. S.; Goldberg, S. B.; Frank, R. C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer
    Meeting Abstract

    Skoulidis, F.; Li, B. T.; Govindan, R.; Dy, G. K.; Shapiro, G.; Bauml, J.; Schuler, M. H.; Addeo, A.; Kato, T.; Besse, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors
    Meeting Abstract

    Sharma, M.; Carvajal, R. D.; Hanna, G. J.; Li, B. T.; Moore, K. N.; Pegram, M. D.; Rasco, D. W.; Spira, A. I.; Alonso, M.; Fang, L.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer
    Meeting Abstract

    Moding, E. J.; Hui, A. B.; Murciano-Goroff, Y. R.; Nabet, B.; Schultz, A.; Qiao, Y.; Li, B. T.; Lin, S. H.; Alizadeh, A. A.; Diehn, M.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01)
    Meeting Abstract

    Li, B. T.; Meric-Bernstam, F.; Puvvada, S. D.; Rowbottom, J.; Jolliffe, D.; Gustavson, M.; Mendoza-Naranjo, A.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer
    Meeting Abstract

    Jee, J.; Lebow, E. S.; Murciano-Goroff, Y. R.; Jayakumaran, G.; Shen, R.; Brannon, A. R.; Benayed, R.; Namakydoust, A.; Offin, M.; Paik, P. K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Li, B. T.; Smit, E. F. F.; Goto, Y.; Nakagawa, K.; Udagawa, H.; Mazieres, J.; Nagasaka, M.; Bazhenova, L.; Saltos, A. N.; Felip, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save